As the avian flu continues to move through Asia and threaten the rest of the world, BioCryst Pharmaceuticals Inc.'s Phase I neuraminidase inhibitor garnered a licensing deal with Green Cross Corp. in Korea, where testing of peramivir will yield data to supplement the U.S. results. (BioWorld Today)
